| Professor David J Webb
in medicine in London, I developed an interest in vascular biology,
extended by a research fellowship at the MRC Blood Pressure Unit in
Glasgow. After higher specialist training in internal medicine and
pharmacology, I was appointed as Senior Lecturer in Medicine at
Edinburgh University, and to the Christison Chair of Therapeutics and
Clinical Pharmacology in 1995. I directed Edinburgh University’s
Wellcome Trust Cardiovascular Research Initiative (1998: £7M over 7
years) and created its Centre for Cardiovascular Science (2000), now
the host to one of only 4 UK BHF Centres of Research Excellence (CoRE:
£7.6M award). My research focuses on the vascular endothelium and renal
function in hypertension using knockout models and translational
studies, including deep phenotyping, in man. I ran the first human
trial on a renin inhibitor, and was first to show in translational
studies the potential for PDE5 inhibitors in hypertension, and for
endothelin receptor antagonists in hypertension and proteinuric kidney
disease. My work has been recognised by award of the Silver and Gold
Medals for research, and Lilly Prize, from the British Pharmacological
Society, and by Fellowship of the Academy of Medical Sciences and Royal
Society of Edinburgh. I have supervised over 20 PhDs and 10MDs and a
number of my research fellows have gone on to prestigious clinical
chairs. I am delighted to be leading the Scottish centre within the
Wellcome Trust-funded Translational Medicine and Therapeutics
Initiative, which I believe has the opportunity to make a real
difference to translational medicine skills in the UK.
5 Key Papers:
Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE.
Collecting duct-specific knockout of the endothelin B receptor causes
hypertension and sodium retention. Am J Physiol 2006;291:F1274-80.
Gudmundsdóttir IJ, Lang NN, Boon NA, Ludlam CA, Webb DJ, Fox KA, Newby DE.
Role of the endothelium in the vascular effects of the thrombin receptor
(protease-activated receptor type 1) in humans. J Am Coll Cardiol
Japp AG, Cruden NL, Amer DA, Li YK, Goudie EB, Johnston NR, Sharma S,
Neilson I, Webb DJ, Megson IL, Flapan AD, Newby DE. Vascular effects of
apelin in vivo in man. J Am Coll Cardiol 2008;52:903-13.
Dhaun N, Lilitkarntakul P, Macintyre I, Muilwijk E, Johnston NR, Kluth DC,
Webb DJ, Goddard J. Urinary endothelin-1 in chronic kidney disease and as a
marker of disease activity in lupus nephritis. Am J Physiol
Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J,
Webb DJ. Blood pressure-independent reduction in proteinuria and arterial
stiffness after acute endothelin-A receptor antagonism in chronic kidney
disease. Hypertension 2009;54:113-9.